Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock

Posted by Geri Gentry on Aug 20th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason Rhodes sold 2,160,516 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 3.0%

Shares of NASDAQ DYN opened at $26.78 on Thursday. The stock’s 50 day moving average price is $23.36 and its two-hundred day moving average price is $19.67. Dyne Therapeutics, Inc. has a 52-week low of $11.65 and a 52-week high of $27.31. The stock has a market capitalization of $5.00 billion, a P/E ratio of -8.04 and a beta of 1.07. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its position in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. BlackRock Inc. acquired a new position in Dyne Therapeutics during the 2nd quarter valued at about $275,500,000. Jupiter Topco LLC bought a new position in Dyne Therapeutics in the 2nd quarter worth about $266,634,000. Orbis Allan Gray Ltd bought a new position in Dyne Therapeutics in the 4th quarter worth about $93,926,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Dyne Therapeutics in the second quarter valued at approximately $30,378,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on DYN shares. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday. Finally, Morgan Stanley dropped their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.42.

View Our Latest Analysis on Dyne Therapeutics

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target for Dyne, well above the stock’s recent trading level. The firm’s long-term model still projects a shift from losses to profitability, with estimated EPS of $1.28 in fiscal 2030.
Neutral Sentiment: Dyne’s strong balance-sheet liquidity remains a supporting factor, with a quick ratio of approximately 12 and relatively low debt compared with equity. Institutional investors also own about 96.7% of the shares, indicating substantial professional-investor participation.
Negative Sentiment: HC Wainwright significantly reduced its EPS forecasts across 2026–2030. Estimates were lowered to losses of $0.98 per share for Q3 2026, $1.01 for Q4, $3.82 for full-year 2026, $3.28 for 2027, $1.91 for 2028 and $0.49 for 2029. Its 2030 profit estimate was also cut to $1.28 from $2.26, signaling expectations for a slower path to profitability.
Negative Sentiment: Director Jason Rhodes sold 426,412 shares at an average price of $26.20, worth approximately $11.2 million, reducing his direct ownership by 36.2%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may reduce its significance as a discretionary bearish signal, but the transaction can still pressure sentiment.
Negative Sentiment: Dyne previously reported quarterly EPS of negative $1.08, missing the consensus estimate of negative $0.75. The company remains a clinical-stage biotechnology business with no established commercial revenue base, making future stock performance highly dependent on clinical progress and funding expectations.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.